Page 1098 - Hematology_ Basic Principles and Practice ( PDFDrive )

969.e12 Part VII Hematologic Malignancies

494. Prebet T, Sun Z, Figueroa ME, et al: Prolonged administration of of myelodysplastic syndromes: an evidence-based review. Biol Blood
azacitidine with or without entinostat for myelodysplastic syndrome Marrow Transplant 15(2):137–172, 2009.
and acute myeloid leukemia with myelodysplasia-related changes: 514. Hahn T, McCarthy PL, Hassebroek A, et al: Significant improvement
results of the US Leukemia Intergroup trial E1905. J Clin Oncol in survival after allogeneic hematopoietic cell transplantation during
32(12):1242–1248, 2014. a period of significantly increased use, older recipient age, and use of
495. Qin T, Castoro R, El Ahdab S, et al: Mechanisms of resistance to unrelated donors. J Clin Oncol 31(19):2437–2449, 2013.
decitabine in the myelodysplastic syndrome. PLoS ONE 6(8):e23372, 515. Brunner AM, Kim HT, Coughlin E, et al: Outcomes in patients age
2011. 70 or older undergoing allogeneic hematopoietic stem cell transplanta-
496. Steensma DP, Baer MR, Slack JL, et al: Multicenter study of decitabine tion for hematologic malignancies. Biol Blood Marrow Transplant
administered daily for 5 days every 4 weeks to adults with myelo- 19(9):1374–1380, 2013.
dysplastic syndromes: the alternative dosing for outpatient treatment 516. Cutler CS, Lee SJ, Greenberg P, et al: A decision analysis of allogeneic
(ADOPT) trial. J Clin Oncol 27(23):3842–3848, 2009. bone marrow transplantation for the myelodysplastic syndromes:
497. Kantarjian H, Issa J-PJ, Rosenfeld CS, et al: Decitabine improves delayed transplantation for low-risk myelodysplasia is associated with
patient outcomes in myelodysplastic syndromes: results of a phase III improved outcome. Blood 104(2):579–585, 2004.
randomized study. Cancer 106(8):1794–1803, 2006. 517. Sierra J, Pérez WS, Rozman C, et al: Bone marrow transplantation
498. Kantarjian H, Oki Y, Garcia-Manero G, et al: Results of a randomized from HLA-identical siblings as treatment for myelodysplasia. Blood
study of 3 schedules of low-dose decitabine in higher-risk myelo- 100(6):1997–2004, 2002.
dysplastic syndrome and chronic myelomonocytic leukemia. Blood 518. Castro-Malaspina H, Harris RE, Gajewski J, et al: Unrelated donor
109(1):52–57, 2007. marrow transplantation for myelodysplastic syndromes: outcome
499. Saunthararajah Y, Sekeres M, Advani A, et al: Evaluation of noncy- analysis in 510 transplants facilitated by the National Marrow Donor
totoxic DNMT1-depleting therapy in patients with myelodysplastic Program. Blood 99(6):1943–1951, 2002.
syndromes. J Clin Invest 2015. 519. Majhail NS, Brunstein CG, Shanley R, et al: Reduced-intensity
500. Quesnel B, Fenaux P: P15INK4b gene methylation and myelodysplas- hematopoietic cell transplantation in older patients with AML/MDS:
tic syndromes. Leuk Lymphoma 35(5–6):437–443, 1999. umbilical cord blood is a feasible option for patients without HLA-
501. Follo MY, Russo D, Finelli C, et al: Epigenetic regulation of nuclear matched sibling donors. Bone Marrow Transplant 47(4):494–498, 2012.
PI-PLCbeta1 signaling pathway in low-risk MDS patients during 520. Di Stasi A, Milton DR, Poon LM, et al: Similar transplantation
azacitidine treatment. Leukemia 26(5):943–950, 2012. outcomes for acute myeloid leukemia and myelodysplastic syndrome
502. Figueroa ME, Skrabanek L, Li Y, et al: MDS and secondary AML patients with haploidentical versus 10/10 human leukocyte antigen-
display unique patterns and abundance of aberrant DNA methylation. matched unrelated and related donors. Biol Blood Marrow Transplant
Blood 114(16):3448–3458, 2009. 20(12):1975–1981, 2014.
503. Fandy TE, Herman JG, Kerns P, et al: Early epigenetic changes and 521. Koreth J, Pidala J, Perez WS, et al: Role of reduced-intensity condition-
DNA damage do not predict clinical response in an overlapping ing allogeneic hematopoietic stem-cell transplantation in older patients
schedule of 5-azacytidine and entinostat in patients with myeloid with de novo myelodysplastic syndromes: an international collaborative
malignancies. Blood 114(13):2764–2773, 2009. decision analysis. J Clin Oncol 31(21):2662–2670, 2013.
504. Quintas-Cardama A, Santos F, Garcia-Manero G: Histone deacetylase 522. Alyea EP, Kim HT, Ho V, et al: Impact of conditioning regimen inten-
inhibitors for the treatment of myelodysplastic syndrome and acute sity on outcome of allogeneic hematopoietic cell transplantation for
myeloid leukemia. Leukemia 25(2):226–235, 2011. advanced acute myelogenous leukemia and myelodysplastic syndrome.
505. Kuendgen A, Strupp C, Aivado M, et al: Treatment of myelodysplastic Biol Blood Marrow Transplant 12(10):1047–1055, 2006.
syndromes with valproic acid alone or in combination with all-trans 523. Appelbaum FR, Anderson J: Allogeneic bone marrow transplantation
retinoic acid. Blood 104(5):1266–1269, 2004. for myelodysplastic syndrome: outcomes analysis according to IPSS
506. Prebet T, Vey N: Vorinostat in acute myeloid leukemia and myelo- score. Leukemia 12(Suppl 1):S25–S29, 1998.
dysplastic syndromes. Expert Opin Investig Drugs 20(2):287–295, 524. Armand P, Kim HT, DeAngelo DJ, et al: Impact of cytogenetics on
2011. outcome of de novo and therapy-related AML and MDS after allo-
507. Ottmann O, DeAngelo D, Garcia-Manero G, et al: Determination geneic transplantation. Biol Blood Marrow Transplant 13(6):655–664,
of a phase II dose of panobinostat in combination with 5-azacitidine 2007.
in patients with myelodysplastic syndromes, chronic myelomonocytic 525. Scott BL, Park JY, Deeg HJ, et al: Pretransplant neutropenia is associ-
leukemia, or acute myeloid leukemia. Blood Meet Extr 459:118, ated with poor-risk cytogenetic features and increased infection-related
2011. mortality in patients with myelodysplastic syndromes. Biol Blood
508. Cashen A, Juckett M, Jumonville A, et al: Phase II study of the histone Marrow Transplant 14(7):799–806, 2008.
deacetylase inhibitor belinostat (PXD101) for the treatment of myelo- 526. Gerds AT, Gooley TA, Estey EH, et al: Pretransplantation therapy with
dysplastic syndrome (MDS). Ann Hematol 91(1):33–38, 2012. azacitidine vs induction chemotherapy and posttransplantation outcome
509. Sekeres MA, Othus M, List AF, et al: A randomized phase II study of in patients with MDS. Biol Blood Marrow Transplant 18(8):1211–1218,
azacitidine combined with lenalidomide or with vorinostat vs. azaciti- 2012.
dine monotherapy in higher-risk myelodysplastic syndromes (MDS) 527. De Witte T, Van Biezen A, Hermans J, et al: Autologous bone marrow
and chronic myelomonocytic leukemia (CMML): North American transplantation for patients with myelodysplastic syndrome (MDS) or
Intergroup Study SWOG S1117. Blood 124:LBA–5, 2014. acute myeloid leukemia following MDS. Chronic and Acute Leukemia
510. Beran M, Shen Y, Kantarjian H, et al: High-dose chemotherapy in Working Parties of the European Group for Blood and Marrow Trans-
high-risk myelodysplastic syndrome: covariate-adjusted comparison of plantation. Blood 90(10):3853–3857, 1997.
five regimens. Cancer 92(8):1999–2015, 2001. 528. de Witte T, Suciu S, Brand R, et al: Autologous stem cell transplanta-
511. Cortes J, Kantarjian H, Albitar M, et al: A randomized trial of liposo- tion in myelodysplastic syndromes. Semin Hematol 44(4):274–277,
mal daunorubicin and cytarabine versus liposomal daunorubicin and 2007.
topotecan with or without thalidomide as initial therapy for patients 529. Ogata K, Nomura T: Application of low-dose etoposide therapy for
with poor prognosis acute myelogenous leukemia or myelodysplastic myelodysplastic syndromes. Leuk Lymphoma 12(1–2):35–39, 1993.
syndrome. Cancer 97(5):1234–1241, 2003. 530. Mario AD, Pagano L, Mele L, et al: Use of gemcitabine (GEM) in
512. Beran M, Estey E, O’Brien S, et al: Topotecan and cytarabine is an advanced myelodysplastic syndromes. Ann Oncol 12(10):1494, 2001.
active combination regimen in myelodysplastic syndromes and chronic 531. Denzlinger C, Bowen D, Benz D, et al: Low-dose melphalan induces
myelomonocytic leukemia. J Clin Oncol 17(9):2819–2830, 1999. favourable responses in elderly patients with high-risk myelodysplastic
513. Oliansky DM, Antin JH, Bennett JM, et al: The role of cytotoxic syndromes or secondary acute myeloid leukaemia. Br J Haematol
therapy with hematopoietic stem cell transplantation in the therapy 108(1):93–95, 2000.